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Abstract 
The time period during which patients manifest psychotic or unspecific symptoms 
prior to treatment (duration of untreated psychosis, DUP, and the duration of 
untreated illness, DUI) has been found to be moderately associated with poor clinical 
and social outcome. Equivocal evidence exists of an association between DUP/DUI 
and structural brain abnormalities, such as reduced hippocampus volume (HV), 
pituitary volume (PV) and grey matter volume (GMV). Thus, the goal of the present 
work was to examine if DUP and DUI are associated with abnormalities in HV, PV 
and GMV. Using a region of interest (ROI) based approach, we present data of 39 
patients from the Basel FePsy (Früherkennung von Psychosen, early detection of 
psychosis) study for which information about DUP, DUI and HV, PV and GMV data 
could be obtained. Twenty-three of them were first episode psychosis (FEP) and 16 
at-risk mental state (ARMS) patients who later made the transition to frank psychosis. 
In unadjusted analyses, we found a significant positive correlation between DUP and 
PV in FEP patients. However, when adjusted for covariates, we found no significant 
correlation between DUP or DUI and HV, PV or GMV anymore. There only was a 
trend for decreasing GMV with increasing DUI in FEP. Our results do not 
comprehensively support the hypothesis of a “toxic” effect of the pathogenic 
mechanism underlying untreated psychosis on brain structure. If there is any effect, it 
might rather occur very early in the disease process, during which patients 
experience only unspecific symptoms.  
 
Keywords: first episode psychosis, at-risk mental state; grey matter volume, 
hippocampal volume; pituitary volume 
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1. Introduction 
Patients with psychosis often experience unspecific and psychotic symptoms for long 
periods before appropriate antipsychotic treatment is initiated (Fusar-Poli et al., 
2013). The time period between first self-perceived signs of a change in well-being or 
unspecific symptoms and treatment is called "duration of untreated illness” (DUI); the 
time period between the development of the first psychotic symptoms and treatment 
is called “duration of untreated psychosis” (DUP) (Norman and Malla, 2001). Longer 
DUP and DUI have been consistently found to be associated with poor clinical and 
social outcomes, hence the need for early intervention services which create better 
outcomes in the critical period of the first 2-5 years of the disease (Bangalore et al., 
2009; Crumlish et al., 2009; Harris et al., 2005; Keshavan et al., 2003; Marshall et al., 
2005; Norman and Malla, 2001; Perkins et al., 2005). It has been hypothesized, that 
this might be due to a “toxic” effect of ongoing, untreated psychosis, respectively the 
effect of the untreated pathogenic mechanism underlying psychotic symptoms (Wyatt 
and Henter, 2001). The investigation if brain volume is affected in the early phases of 
psychosis has therefore become an important focus of research. 
To better understand this possible process, several research groups have 
investigated the relationship between DUP and different brain structures (Büschlen et 
al., 2011; Crespo-Facorro et al., 2007a; Crespo-Facorro et al., 2007b; Ho et al., 
2005; Ho et al., 2003; Hoff et al., 2000; Lappin et al., 2006; Takahashi et al., 2007). 
The results of these studies were summarized in two systematic reviews (Anderson 
et al., 2015; Rund, 2014), both finding minimal evidence for the “neurotoxicity” 
hypothesis. Rund et al. (2014) suggested in his review that there might be a 
threshold value for a toxic effect of psychosis rather than a linear relationship 
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between DUP and a neurotoxic effect and that several of the evaluated studies might 
not have had a long enough DUP to detect a toxic effect of active psychosis (Rund, 
2014).  
One of the key regions to be investigated is the hippocampus, which is involved in 
memory functions and complex behaviors, including stress responses (Small et al., 
2011), and has been proposed to be important in the development of schizophrenia 
(Antonova et al., 2004; Heckers and Konradi, 2002; Koolschijn et al., 2010; Phillips et 
al., 2002). It is among the most consistently reported abnormal brain regions in 
schizophrenia (Adriano et al., 2012) and highly interconnected with other regions of 
the brain. There is some evidence suggesting a change of the hippocampal volume 
(HV) during the early stages of a psychotic disorder. HV has been found to be 
decreased in patients with first episode psychosis (FEP) and patients with an at-risk 
mental state (ARMS) for psychosis (e.g. Buehlmann et al., 2010; Dean et al., 2016; 
Wood et al., 2010) compared to healthy controls (HC) (Adriano et al., 2012) . 
Although it might be inferred from these findings that there is a time period at the 
beginning of the disease in which HV changes, it is yet unknown whether and when 
such changes actually occur. According to the “neurotoxicity” hypothesis, HV 
changes would be expected to increase the longer untreated symptoms persist. 
Nonetheless, to our knowledge no clear association between DUP and HV has been 
found up to now (Ho et al., 2005). 
Another region that has been investigated recently and which seems to be affected in 
the early stages of the disease is the pituitary volume (PV) (Büschlen et al., 2011). A 
recent meta-analysis of studies investigating the volumes of the pituitary in patients 
with schizophrenia, FEP, schizotypical disorder or ARMS and healthy controls found 
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a trend for larger PVs in both ARMS patients with later transition to psychosis and 
FEP patients compared to HC (Nordholm et al., 2013). Whether there is an 
association between the duration of untreated symptoms and volume changes in the 
pituitary is still unclear due to inconsistent results. 
Several studies have also found volumetric changes of various grey matter regions in 
early stages of psychosis and ARMS (Borgwardt et al., 2007; Borgwardt et al., 2008; 
Chua et al., 2007; de Castro-Manglano et al., 2011; Witthaus et al., 2009). 
Investigations on the correlation between DUP and grey matter volume (GMV) 
changes have yielded equivocal results (Ho et al., 2003; Hoff et al., 2000; Lappin et 
al., 2006; Malla et al., 2011; Penttila et al., 2010; Takahashi et al., 2007).  
Studies investigating a possible correlation of DUI and GMV abnormalities found 
similar equivocal results. Bangalore et al. found a significant inverse correlation 
between DUI and the volume of some grey matter regions (Bangalore et al., 2009), 
Velakoulis et al. found right medial temporal, medial cerebellar and bilateral anterior 
cingulate GMV changes, and white matter volume loss in the right posterior limb of 
the internal capsule associated with a longer DUI (Velakoulis et al., 2002), whereas 
Hoff et al. (2000) could not find an significant correlation between changes in GMV 
and DUI. In line with the hypothesis of a “neurotoxicity” of untreated psychosis, it 
might be surmised that the longer untreated psychotic processes/symptoms persist, 
the more pronounced structural alterations of HV, PV and GMV could be. 
The objective of the present study was to investigate a possible correlation between 
DUP/DUI and different structural brain abnormalities (HV, PV and GMV) that have 
been found to be affected in early stages of psychosis. On the basis of previous 
longitudinal studies of DUP and other volume abnormalities in early stages of 
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psychosis, we tested the hypothesis that a longer DUP or DUI would be associated 
with a decrease in HV, PV and GMV. This is the first study to look at the relationship 
between all three brain parts, HV, PV and GMV, and DUP/DUI in the same study. 
Additionally, in contrast to most other studies, this study mainly includes 
antipsychotic-free subjects, which is highly relevant due to the fact that antipsychotic 
treatment itself can lead to brain structural changes (Vita et al., 2015). 
2. Methods 
2.1. Participants 
 
This study was part of the FePsy (Früherkennung von Psychosen; early detection of 
psychosis) study (Riecher-Rössler et al., 2007), a multi-domain study on the early 
detection of psychosis. Subjects with an ARMS or FEP were recruited from a service 
area covering about 200,000 inhabitants in and around Basel, Switzerland, into the 
study via the FePsy Clinic at the University Hospital Basel, which was set up 
specifically to identify, assess and treat individuals in the early stages of psychosis. 
The study design and criteria for identification of ARMS and FEP subjects have been 
described in detail previously (Riecher-Rössler et al., 2007).  
The study sample overlaps with previous samples reported on from the FePsy study 
(Borgwardt et al., 2006; Buehlmann et al., 2010; Büschlen et al., 2011; Riecher-
Rössler et al., 2007; Walter et al., 2012b; Walter et al., 2014). The study was 
approved by the Ethics Committee of Basel, Switzerland (EKBB) and written 
informed consent was obtained from the participants.  
In this study, we present data of 39 patients from the Basel FePsy study for which 
information about DUP, DUI and region of interest (ROI) data could be obtained. 
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Twenty-three patients were identified as FEP patients and 16 as ARMS individuals 
who later made the transition to frank psychosis (ARMS-T). The service is fully 
responsible for all ARMS and FEP patients of a catchment area (Kanton Basel-
Stadt). Our study sample did not significantly differ from all patients of our service in 
the respective period regarding sociodemographic characteristics. 
Screening procedure 
For screening purposes and measuring the severity of (pre-)psychotic phenomena, 
we used the Basel Screening Instrument for Psychosis (BSIP) (Riecher-Rössler et 
al., 2008). Individuals were assessed and classified as individuals with an ARMS, 
FEP or “not at risk for psychosis” (other psychiatric diseases). All assessments were 
conducted by experienced psychiatrists/psychologists who underwent regular 
training.  
Inclusion criteria  
We included FEP patients and ARMS individuals who later made the transition to 
frank psychosis (ARMS-T) according to the PACE (Personal Assessment and Crisis 
Evaluation) criteria proposed by Yung et al. (1998) (Yung et al., 1998) which have 
also been employed in previous MRI studies of patients with an ARMS (Borgwardt et 
al., 2006; Garner et al., 2005; Pantelis et al., 2003; Velakoulis et al., 2006).  
Exclusion criteria 
Patients aged below 18 years with insufficient knowledge of German, IQ below 70, a 
previous episode of schizophrenic psychosis (treated with antipsychotics for more 
than 3 weeks), a psychosis due to organic reasons or substance dependency and 
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psychotic symptoms within a clearly diagnosed affective psychosis or borderline 
personality disorder were excluded from the study. 
2.2. Acquisition and analysis of MRI data  
 
All participants received MRI within an average 25 days after entering into our early 
detection service. 
Since this study is a part of the FePsy project, the acquisition of the presented MRI 
data has already been described elsewhere (Buehlmann et al., 2010; Büschlen et al., 
2011). 
Briefly, a SIEMENS (Erlangen, Germany) MAGNETOM VISION 1.5 T scanner was 
used at the University Hospital Basel to scan all subjects at the inclusion to the study, 
i.e. when they first presented with prodromal or psychotic symptoms. Foam padding 
and velcro straps were used to minimize head movement. A three-dimensional 
volumetric spoiled gradient recalled echo sequence generated 176 contiguous, 1 mm 
thick sagittal slices. Imaging parameters were: time-to-echo, 4 ms; time-to-repetition, 
9.7 ms; flip angle, 12; matrix size, 200×256; field of view, 25.6×25.6 cm matrix; voxel 
dimensions, 1.28×1×1 mm.  
A detailed description of the measuring processes of the regions of interest (ROI) 
and GMV used in this sample has been published elsewhere (Harris et al., 2005; 
Phillips et al., 2002). In summary, a ROI approach was used to measure HV and PV 
manually by a single tracer with a mouse-driven cursor, using the interactive public 
domain software program AMIRA which displays all three planes simultaneously 
(Kappos et al., 2006). All measurements of HV and PV were carried out by a trained 
and blinded rater (AW). The intra-rater intra-class correlation coefficient and inter-
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rater reliability have been reported in our previously published studies (Walter et al., 
2012a; Walter et al., 2014). To assess GMV, a voxel-based morphometry, using the 
fully automated software SIENAX (www.fmrib.ox.ac.uk/fsl), allowed us to estimate 
the whole brain volumes from a single image, normalized for skull size (Smith et al., 
2007) . After stripping non-brain tissue, the software estimates the scaling between 
the subject’s image and standard space using the brain and skull images. It then runs 
tissue segmentation to estimate the volume of brain tissue and multiplies this by the 
estimated scaling factor to reduce head-size-related variability between subjects 
(Smith et al., 2002). 
2.3. DUP and DUI 
 
DUI was defined as the time period between first self-perceived signs of a change in 
well-being and first contact with our specialized early detection service. DUP was 
defined as the time period between the appearance of the first positive psychotic 
symptom and first contact with our specialized early detection service. DUP was only 
assessed in FEP patients because it was almost zero in our ARMS-T patients due to 
our close follow-up during the at-risk mental state and prompt treatment at transition. 
DUI was determined by using the Basel Interview for Psychosis (BIP) (Riecher-
Rössler et al., 2015; Riecher-Rössler et al., 2007), a structured and specifically 
developed interview for the early detection of psychosis, allowing an exact 
description of the onset of all symptoms. The DUP was assessed using the Basel 
Screening Interview for Psychosis (BSIP) (Riecher-Rössler et al., 2008). 
Both DUP and DUI were assessed according to the patient's subjective response but 
also by using other available information resources (e.g. information from family 
members, medical histories). 
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Psychopathology measures 
Positive symptoms were assessed with the 4 items: hallucinations, suspiciousness, 
unusual thought content, and conceptual disorganization of the Brief Psychiatric 
Rating Scale (BPRS) (Ventura et al., 1993). Negative symptoms were assessed with 
the Scale for the Assessment of Negative Symptoms (SANS) (Andreasen, 1983).  
2.4. Statistical analysis of clinical and demographic data 
 
Statistical analyses were performed using the R environment for statistical computing 
(R Development Core Team, 2012). Due to a strong positive skew, both DUP and 
DUI were anchored at 1 and then log transformed. Two tailed t-tests for the 
continuous and Fisher’s Exact or 2 tests for the categorical variables were used in 
order to compare groups for demographic and clinical data (p<0.05). 
Associations of brain structural volumes with DUP and DUI were analyzed using 
linear regression and mixed effects (LME) models, in which log transformed DUP or 
DUI served as outcome variables and brain structural volumes as predictors. Linear 
regression models were used for PV and whole brain GMV and LME models for HV. 
LME models were used in the latter case to account for repeated measures resulting 
from assessing HV at both the left and right hemispheres. The within subject factor 
hemisphere and the interaction between hemisphere and DUI/DUP was therefore 
included in all LME models. The random effect structure of the LME models 
consisted of a random intercept per subject. 
All models included age and gender as covariates. Models with PV and HV as 
outcome variables additionally included whole brain volume as covariate. 
Furthermore, models with DUI included group (ARMS-T vs. FEP) and group x DUI 
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interaction terms and in case of HV group x hemisphere and group x hemisphere x 
DUI interaction terms. All continuous variables were z-transformed before entering 
the models to get fully standardized regression coefficients for continuous variables 
and y-standardized regression coefficients for binary variables. 
3. Results  
In this paper we present data of 39 individuals (23 FEP, 16 ARMS-T) screened 
between 01.03.2000 and 29.2.2004, in whom the MRI scans were completed. The 
sociodemographic, clinical characteristics and diagnoses of the sample are 
presented in Table 1. As was to be expected, the BPRS score was higher in FEP 
than in ARMS-T patients (p = 0.024), while the SANS score did not differ significantly 
between the two groups (p = 0.648).  
The median DUP (only assessed in FEP) was 3.7 months (mean: 11.3; SD: 16.6). 
The median DUI for the total sample was 36 months (mean: 52.5; SD: 59.1), 51 
months (mean: 47.9; SD: 37.7) for ARMS-T and 27 months (mean: 55.8; SD: 71.6) 
for FEP.  
ARMS-T patients had significantly bigger left HV than FEP patients (p = 0.020). 
There were no significant differences between the ARMS-T and FEP groups in the 
right HV, PV, and GMV. 
Table 2 displays regression coefficients and p-values of the models testing 
associations between DUP and brain structural volumes in FEP patients. DUP was 
not significantly associated with HV, PV and GMV in FEP patients when adjusted for 
confounders (age, sex, whole brain volume). However, when the model was only 
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adjusted for whole brain volume, there was a positive relationship between DUP and 
PV (p = 0.042). 
Four (25%) of the ARMS-T patients and 9 (39%) of the FEP patients were taking 
antipsychotics at the time of MRI assessment. Additionally, one ARMS-T patient had 
been taking antipsychotics before but not during the MRI assessment. All other 
patients were antipsychotic-naïve. Since according to our inclusion criteria patients 
were only allowed to have taken antipsychotics for up to three weeks at the time of 
inclusion, all patients were treated for a relatively short period of time. Moreover, 
patients were exclusively treated with low to moderate doses of either olanzapine or 
risperidone.  
Table 3 displays the results of the models testing associations between DUI and 
brain structural volumes in FEP and ARMS-T patients combined. DUI was not 
significantly associated with PV and HV and – as indicated by non-significant 
interaction terms – the effect of DUI was not moderated by group (FEP vs. ARMS-T) 
or hemisphere (left vs. right) in these volumes. For whole brain volume, there was a 
significant interaction between group and DUI (p = 0.027), indicating different 
associations between DUI and whole brain volumes in ARMS-T and FEP patients. 
We therefore performed separate regression models for ARMS-T and FEP patients 
and found that there was a trend for decreased gray matter volume with increasing 
DUI in FEP (p = 0.093) but not in ARMS-T patients. When the model was calculated 
without adjusting for confounders, the results did not change significantly. 
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4. Discussion 
Using an ROI-based approach we investigated associations between PV, HV, GMV 
and DUP/DUI. To our knowledge, our study is one of the first to investigate the effect 
of DUI/DUP on HV, PV and GMV in the same patients. Our study did not find 
associations between DUP/DUI and brain volume which confirms findings of many 
earlier studies.  
In accordance with other studies (Ho et al., 2005; Takahashi et al., 2007) we found 
that HV was neither significantly associated with DUP nor with DUI. Penttilä et al. 
(Penttila et al., 2010) found a correlation between DUP and the right HV that we 
could not replicate. One possible explanation for this discrepancy is that in their study 
the MRI was taken many years after the ending of DUP (mean duration between 
onset of treatment and MRI scan of more than 10 years), whereas in our study the 
MRI was conducted at baseline (i.e. immediately before treatment initiation). Thus, it 
is possible that a longer DUP might affect the right HV only at a later stage of the 
illness. 
In the unadjusted analysis, there was a significant positive correlation between DUP 
and PV. However, we found no association between DUP/DUI and PV when 
adjusted for covariates. An increased PV has been found in the prodromal phase 
(Garner et al., 2005; Pariante et al., 2005; Pariante et al., 2004) and the early stages 
of psychotic disease (Büschlen et al., 2011; Walter et al., 2014). From our results it is 
not clear whether the duration of untreated psychosis plays a role for this increase. 
Consistent with other studies (Ho et al., 2003; Lappin et al., 2006; Penttila et al., 
2010) we found no correlation between GMV and DUP. The correlation between 
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DUP and GMV Malla et al. (Malla et al., 2011) found might have been due to the 
inclusion of patients with affective psychosis. An analysis of only those individuals 
with schizophrenia found no correlation with DUP in that study either.  
Although our results could not reveal a statistically significant correlation between 
DUI and GMV in both groups, we found a statistical trend for a negative correlation 
between DUI and GMV in the FEP group. This could suggest a possible negative 
association of untreated, very early, non-specific psychiatric symptoms with GMV in 
FEP, which is somewhat in accordance with a meta-analysis investigating the 
relationship between DUI and different GMV areas (Anderson et al., 2015). However, 
from our results, no causal conclusions can be drawn. 
HV, PV and GMV have been found to be altered in the early stages of the illness 
(Büschlen et al., 2011; Koolschijn et al., 2010; Pantelis et al., 2003), thus raising the 
question whether there might be a damaging impact of the prodromal phase or early 
untreated psychosis on said structures. In the last decade, most studies have 
investigated the time period when psychotic symptoms are already apparent (DUP) 
and yielded equivocal results. Generally, such studies were conducted with small 
samples and therefore were underpowered to reliably detect small effects. Thus, the 
replication of known results becomes an important aim in this field of research. Only 
few research groups have expanded their focus and included the prodromal stage 
(DUI), such as we did in our study. 
Different mechanisms causing the neurotoxic effect of psychosis have been 
suggested: e.g. glutamatergic excitotoxicity (de la Fuente-Sandoval et al., 2011), 
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elevated dopamine levels (Keshavan et al., 1998) or persistent catecholaminergic 
activity (Bangalore et al., 2009).  
Another possible reason for volume changes in the first stages of psychosis might be 
hormonal abnormalities, which have consistently been reported (Riecher-Rössler et 
al., 2013; Walker et al., 2008). Increased levels of cortisol have been found in some 
patients with increased risk for psychosis (Walker et al., 2013); such higher levels 
seem to be associated with reduced HV (Mondelli et al., 2010).  
Higher prolactin levels have also been found in antipsychotic-naïve patients with 
schizophrenia (Garcia-Rizo et al., 2012), FEP (Riecher-Rössler et al., 2013) and 
ARMS (Aston et al., 2010; Ittig et al., 2016). Since a higher prolactin production is 
known to be associated with an enlargement of the PV (MacMaster et al., 2007), a 
higher prolactin secretion might explain why increased PV have been found during 
the prodromal phase (Riecher-Rössler et al., 2013). 
It has been hypothesized that the psychological distress during prodromal states and 
emerging psychosis might lead to hyperprolactinemia (Riecher-Rössler et al., 2013) 
and hypercortisolism, which in turn might cause structural changes in PV and HV. In 
line with the hypothesis of a “neurotoxicity” of untreated psychosis, it might be 
surmised that the longer such processes/symptoms and psychological distress 
persist, the more pronounced structural alterations of HV and PV could be. 
Investigations focusing on DUP/DUI and reduced cognitive functioning as another 
possible “toxic” effect have yielded similarly equivocal results regarding the 
“neurotoxicity” hypothesis (Rapp et al., 2013). Other factors (i.e. social decline, 
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substance abuse, etc.) might be responsible for the worse outcome associated with 
longer DUI/DUP (Broussard et al., 2013). 
Besides a “general” neurotoxicity hypothesis, it seems important to maintain that this 
“toxic” process might also only occur in a subgroup of psychosis patients. 
Furthermore, first episode psychosis might be in a too early phase of the disease to 
detect this phenomenon. 
In general, the comparability across studies may be reduced due to different 
anatomic ROI definitions, biases in voxel-based morphometry (Fusar‐Poli et al., 
2013), and different MRI acquisition parameters (e.g. different slice thickness). 
Another methodological problem are the different definitions and measurements of 
DUP and DUI in different studies (Polari et al., 2011), which make comparisons 
difficult, as does the inclusion of different patient groups (e.g. affective psychosis, 
etc.) since some brain volume anomalies might be connected to other symptoms (i.e. 
depressive symptoms) (Koolschijn et al., 2010). It has also been suggested that 
defining DUP just as a period of time might not be enough when investigating a 
possible toxicity of a pathogenic mechanism underlying psychosis, since this 
definition of DUP makes no difference between individuals who experience 
continuous symptoms during DUP and others who suffer symptoms for short periods 
with long intervals before treatment. It is also possible that some individuals with a 
faster progression of the disease suffer greater structural brain changes but are 
hospitalized or treated sooner, resulting in a shorter DUP. Additionally, patients that 
have a reduced GMV might suffer from cognitive deficits that hinders them to get 
access to fast treatment.  
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4.1. Limitations  
As this study has a cross-sectional design, no causal relationships but only 
correlational relationships can be established. On the other hand longitudinal studies 
on this topic seem hardly feasible, as individuals usually do not seek help 
immediately when first symptoms occur. Also, our sample only comprises 39 
patients, so that small effects cannot be detected. This study examined whole grey 
matter volume and hippocampus but did not examine other important cortical areas 
(frontal regions, superior temporal gyrus, etc). Other potentially influencing factors on 
brain volumes apart from the disease could not be controlled for. Since the number of 
tested brain volumes were relatively small and since we had limited power, we did 
not want to further reduce power by performing correction for multiple testing. 
4.2. Conclusions 
We found a significant positive correlation between DUP and PV in FEP patients. 
However, when adjusted for covariates, we found no significant correlation between 
DUP or DUI and HV, PV or GMV anymore. There only was a trend for decreasing 
GMV with increasing DUI in FEP. Our results do therefore not comprehensively 
support the hypothesis of a “toxic” effect of the pathogenic mechanism underlying 
untreated psychosis on brain structure. If there is any effect, it might rather occur 
very early in the disease process, during which patients experience only unspecific 
symptoms (during DUI).  
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18 
 
  
19 
 
 
 
Table 1: Demographic and clinical sample characteristics 
 Combined ARMS-T FEP p-value 
 N=39 N=16 N=23  
Gender:    0.734 
    Women 11 (28.2%) 5 (31.2%) 6 (26.1%)  
    Men 28 (71.8%) 11 (68.8%) 17 (73.9%)  
Age 27.1 (6.4) 26.8 (6.6) 27.2 (6.5) 0.848 
Years of education 10.3 (2.8) 10.7 (2.2) 10.0 (3.2) 0.464 
BPRS total score 46.8 (11.9) 41.8 (9.4) 50.5 (12.4) 0.024 
SANS total score 32.0 (18.8) 30.3 (18.4) 33.1 (19.5) 0.648 
Diagnoses
1 
Paranoid Schizophrenia 
Undifferentiated Schizophrenia 
Acute transient psychotic disorder 
Schizoaffective disorder 
Depression with psychotic symptoms 
Missing diagnosis 
 
 
 
2 (12.5%) 
2 (12.5%) 
2 12.5%) 
2 12.5%) 
2 12.5%) 
6 (37.5%) 
 
15 (65.2%) 
1 (4.3%) 
4 (17.4%) 
2 (8.7%) 
 
1 (4.3%) 
 
Duration of untreated psychosis [months] 11.3 (16.6)  11.3 (16.6)  
Duration of untreated illness [months] 52.5 (59.1) 47.9 (37.7) 55.8 (71.6) 0.665 
Hippocampus right volume [mm
3
] 3162 (235) 3194 (216) 3140 (249) 0.470 
Hippocampus left volume [mm
3
] 2841 (256) 2956 (251) 2761 (232) 0.020 
Pituitary volume [mm
3
] 537 (106) 541 (119) 535 (98.5) 0.860 
Grey matter volume [cm
3
] 681 (55.8) 680 (57.5) 681 (55.9) 0.983 
Antipsychotic-naive 25 (64.1%) 11 (68.8%) 14 (60.9%) 0.869 
Antipsychotics currently 13 (33.3%) 4 (25.0%) 9 (39.1%) 0.565 
Chlorpromazine equivalent dose [mg] 250 (153) 262 (149) 244 (163) 0.851 
FEP = First episode psychosis; ARMS-T = Patients with an at-risk mental state for psychosis and 
later transition to psychosis. Categorical variables are presented as absolute numbers and 
percentages in parenthesis and were compared with Chi-square or Fisher's Exact tests. Continuous 
variables are presented with means and standard deviations in parentheses and were compared with 
Welch's two sample t-tests. 
 
1
 Diagnoses in ARMS-T after transition to psychosis 
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Table 2:  Hippocampus, pituitary, and grey matter volumes regressed on duration of 
untreated psychosis (DUP) and other covariates in first episode psychosis (FEP) 
patients 
 
 
Term 
Hippocampus Pituitary Grey matter 
Coef p-value Coef p-value Coef p-value 
DUP (log)  0.016  0.937  0.393  0.073 -0.107  0.530   
DUP (log) x Hemisphere  0.096  0.577     
Age -0.277  0.224 -0.056  0.805 -0.488  0.012*  
Hemisphere  0.262  0.128     
Sex -0.229  0.728  0.002  0.997  1.424  0.002** 
Whole brain volume  0.365  0.185  0.259  0.350   
Coef = regression coefficient; DUP = duration of untreated psychosis. Dummy coding of binary 
variables: Sex: men=-0.5, women=0.5; Hemisphere: left=-0.5, right=0.5. All independent and 
dependent variables except binary variables were z-transformed before model fitting. 
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Table 3:  Hippocampus, pituitary, and grey matter volumes regressed on duration of 
untreated illness (DUI) and other covariates in first episode psychosis (FEP) and 
prodromal (ARMS-T) patients combined  
 
Term 
 Hippocampus  Pituitary  Grey matter 
 Coef p-value  Coef p-value  Coef p-value 
DUI (log)  -0.073  0.689    0.118  0.499     0.039  0.813  
DUI (log) x Group   0.147  0.701    0.079  0.829    -0.741  0.027* 
DUI (log) x Group x Hemisphere   0.184  0.460        
DUI (log) x Hemisphere  -0.012  0.923        
Age  -0.229  0.152    0.027  0.859    -0.268  0.065  
Group  -0.494  0.127   -0.125  0.683    -0.046  0.871  
Group x Hemisphere   0.560  0.016*       
Hemisphere  -0.020  0.861        
Sex   0.028  0.941   -1.058  0.007**   0.772  0.019* 
Whole brain volume   0.170  0.356    0.244  0.171      
Coef = regression coefficient; DUP = duration of untreated psychosis. Dummy coding of binary 
variables: Sex: men=-0.5, women=0.5; Hemisphere: left=-0.5, right=0.5; Group: ARMS-T=-0.5, 
FEP=0.5. All independent and dependent variables except binary variables were z-transformed before 
model fitting. 
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